+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Metastatic Melanoma Therapeutics Market, by Therapy, by Stages, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

  • PDF Icon

    Report

  • 168 Pages
  • August 2021
  • Region: Global
  • Coherent Market Insights Pvt Ltd.
  • ID: 5417333
Melanoma is a severe form of cancer, commonly known as skin cancer. The population residing at higher altitude levels or in the close proximity to the equator, are the most susceptible to melanoma, as the symptoms are prominently initiated post-exposure to Ultraviolet (UV) radiation that results in blistering sunburns. If diagnosed early in stage 0, melanoma can be surgically cured to almost 100%; however, when the disease metastizes in a body, it becomes strenuous to treat it due to the availability of a restricted range of treatment options. The selection of treatment line or systemic drug therapy entirely depends on the stage of melanoma.



Metastatic melanoma is the most severe stage (IV) of skin cancer that occurs when melanoma penetrates the skin deeper to reach various parts of a body, predominantly the subcutaneous tissue layer under the skin, lungs, bones, liver, brain, and lymph nodes. In the most severe case of metastasis, the gastrointestinal tract, adrenal glands, spleen, and heart can also be affected. Currently, only a limited set of therapies are available to promisingly treat burgeoning cases of metastatic melanoma patients. The disease thus requires more efficient and effective treatment options.

Market Dynamics


High incidence of melanoma leading to large patient pool is one major factor driving the global metastatic melanoma therapeutics market growth. Melanoma of the skin is the 19th most prevalent cancer in both men and women, according to the World Cancer Research Fund. Globally, the number of cases reported were nearly 300,000 new cases in 2018, which will boost the growth of global metastatic melanoma therapeutics market.

Key features of the study:

  • This report provides in-depth analysis of the global metastatic melanoma therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the metastatic melanoma therapeutics market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
  • Key companies covered as a part of this study include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG., Amgen Inc., AstraZeneca, Daiichi Sankyo Company, Limited., AB Sciences., AgonOX, Inc., Eisai Co., Ltd, GlaxoSmithKline, plc., Pfizer, Inc., and Vical, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global metastatic melanoma therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the metastatic melanoma therapeutics market

Detailed Segmentation:


Global Metastatic melanoma therapeutics Market, By Therapy:

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Surgery

Global Metastatic melanoma therapeutics Market, By Stages:

  • Stage 0
  • Stage I
  • Stage II
  • Stage III
  • Stage IV

Global Metastatic melanoma therapeutics Market, By End User:

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

Global Metastatic melanoma therapeutics Market, By Region:

  • North America
  • By Country
  • U.S.
  • Canada
  • Latin America
  • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Country/Region
  • South Africa
  • Central Africa
  • North Africa

Company Profiles

  • Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Novartis AG
  • Merck & Co., Inc.
  • Genentech Inc.
  • F. Hoffmann-La Roche AG.
  • Amgen Inc.
  • AstraZeneca
  • Daiichi Sankyo Company, Limited.
  • AB Sciences.
  • AgonOX, Inc.
  • Eisai Co., Ltd
  • GlaxoSmithKline, plc.
  • Pfizer, Inc.
  • Vical, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Frequently Asked Questions about the Metastatic Melanoma Therapeutics Market

What is the estimated value of the Metastatic Melanoma Therapeutics Market?

The Metastatic Melanoma Therapeutics Market was estimated to be valued at $6432.3 Million in 2021.

What is the growth rate of the Metastatic Melanoma Therapeutics Market?

The growth rate of the Metastatic Melanoma Therapeutics Market is 11.6%, with an estimated value of $13828.9 Million by 2028.

What is the forecasted size of the Metastatic Melanoma Therapeutics Market?

The Metastatic Melanoma Therapeutics Market is estimated to be worth $13828.9 Million by 2028.

Who are the key companies in the Metastatic Melanoma Therapeutics Market?

Key companies in the Metastatic Melanoma Therapeutics Market include Bristol, Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann, La Roche AG., Amgen Inc. and Daiichi Sankyo Company, Limited..

Table of Contents

1. Research Objectives and Assumptions
  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview
  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snapshot, By Therapy
  • Market Snapshot, By Stages
  • Market Snapshot, By End User
  • Market Snapshot, By Region
  • Market Opportunity Map

3. Global Metastatic Melanoma Therapeutics Market Insights
  • Drivers
  • Restraints
  • Opportunity
  • Impact Analysis
  • Pipeline Analysis
  • Market Trends
  • Recent Product Approvals/ Launch
  • Key Developments
  • Regulatory Scenario
  • Collaborations & Acquisitions
  • Epidemiology
  • PEST Analysis

4. Global Metastatic Melanoma Therapeutics Market- COVID-19 Impact Analysis
  • Economic Impact
  • COVID-19 Epidemiology
  • Impact of COVID-19 on demand and supply chain

5. Global Metastatic Melanoma Therapeutics Market, By Therapy, 2017 - 2028 (US$ Million)
  • Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2018 - 2028
  • Segment Trends
  • Chemotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million)
  • Immunotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million)
  • Targeted Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million)
  • Radiation Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million)
  • Surgery
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million)

6. Global Metastatic Melanoma Therapeutics Market, By Stages, 2017 - 2028 (US$ Million)
  • Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2018 - 2028
  • Segment Trends
  • Stage 0
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million)
  • Stage I
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million)
  • Stage II
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million)
  • Stage III
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million)
  • Stage IV
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million)

7. Global Metastatic Melanoma Therapeutics Market, By End User, 2017 - 2028 (US$ Million)
  • Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2018 - 2028
  • Segment Trends
  • Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million)
  • Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million
  • Home Healthcare
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million)
  • Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028 (US$ Million)

8. Global Metastatic Melanoma Therapeutics Market, By Region, 2017 - 2028 (US$ Million)
  • Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2018 - 2028
  • Region at Trends
  • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2028, (US$ Million)
  • U.S.
  • Canada
  • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2028, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2028, (US$ Million)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2028, (US$ Million)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2028, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country/Region, 2017-2028, (US$ Million)
  • South Africa
  • Central Africa
  • North Africa

9. Competitive Snapshot
Company Profiles
  • Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Genentech Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • F. Hoffmann-La Roche AG.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Daiichi Sankyo Company, Limited.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • AB Sciences.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • AgonOX, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Eisai Co., Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • GlaxoSmithKline, plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Pfizer, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Vical, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section
  • Research Methodology
  • About us

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bristol-Myers Squibb Company
  • Novartis AG
  • Merck & Co., Inc.
  • Genentech Inc.
  • F. Hoffmann-La Roche AG.
  • Amgen Inc.
  • AstraZeneca
  • Daiichi Sankyo Company, Limited.
  • AB Sciences.
  • AgonOX, Inc.
  • Eisai Co., Ltd
  • GlaxoSmithKline, plc.
  • Pfizer, Inc.
  • Vical, Inc.